Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn’s Disease in China

被引：0
|
作者：
Haotian Chen
Jihao Shi
Yipeng Pan
Zhou Zhang
Hao Fang
Ying Chen
Wendong Chen
Qian Cao
机构：
[1] College of Medicine,Department of Gastroenterology, Sir Run Run Shaw Hospital
[2] Zhejiang University,undefined
[3] Changsha Normin Health Technology Ltd,undefined
[4] Normin Health Consulting Ltd,undefined
来源：
Advances in Therapy | 2020年 / 37卷
关键词：
Chinese; Costs; Crohn’s disease; Infliximab; QALY; Reimbursement; Surgery;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：431 / 449
页数：18
相关论文
共 50 条
  • [1] Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China
    Chen, Haotian
    Shi, Jihao
    Pan, Yipeng
    Zhang, Zhou
    Fang, Hao
    Chen, Ying
    Chen, Wendong
    Cao, Qian
    ADVANCES IN THERAPY, 2020, 37 (01) : 431 - 449
  • [2] Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China
    Ji-Hao Shi
    Liang Luo
    Xiao-Li Chen
    Yi-Peng Pan
    Zhou Zhang
    Hao Fang
    Ying Chen
    Wen-Dong Chen
    Qian Cao
    World Journal of Gastroenterology, 2020, 26 (41) : 6455 - 6474
  • [3] Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China
    Shi, Ji-Hao
    Luo, Liang
    Chen, Xiao-Li
    Pan, Yi-Peng
    Zhang, Zhou
    Fang, Hao
    Chen, Ying
    Chen, Wen-Dong
    Cao, Qian
    WORLD JOURNAL OF GASTROENTEROLOGY, 2020, 26 (41) : 6455 - 6474
  • [4] The cost-effectiveness of infliximab in Crohn's disease
    Smart, Claire
    Selinger, Christian P.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (05) : 589 - 598
  • [5] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [6] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    Advances in Therapy, 2021, 38 : 4233 - 4245
  • [7] Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden
    Hansson-Hedblom, Amanda
    Almond, Chrissy
    Borgstrom, Fredrik
    Sly, Indeg
    Enkusson, Dana
    Buchholt, Anders Troelsgaard
    Karlsson, Linda
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [8] Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
    Amanda Hansson-Hedblom
    Chrissy Almond
    Fredrik Borgström
    Indeg Sly
    Dana Enkusson
    Anders Troelsgaard Buchholt
    Linda Karlsson
    Cost Effectiveness and Resource Allocation, 16
  • [9] Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naive Patients
    Aliyev, Elmar R.
    Hay, Joel W.
    Hwang, Caroline
    PHARMACOTHERAPY, 2019, 39 (02): : 118 - 128
  • [10] THE COST-EFFECTIVENESS OF USTEKINUMAB COMPARED TO INFLIXIMAB AND ADALIMUMAB IN ADULT PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE (TNF NAIVE POPULATION)
    Aliyev, E. R.
    Hay, J. W.
    Hwang, C.
    VALUE IN HEALTH, 2018, 21 : S84 - S84
12345